SHERIDAN, WYOMING -- July 10, 2026 -- Nootropics Depot released a white paper challenging conventional Reishi mushroom quality standards and proposing a new framework centered on bioactive compound groups rather than single marker molecules. CEO Paul Eftang authored the paper, titled "Beyond the Marker: A Bioactives-First Standard for Reishi Quality," which argues that current industry practices prioritize measurement convenience over functional relevance. The company announced the publication on July 9, 2026, positioning the framework as a practical tool for laboratories, manufacturers, and quality assurance teams evaluating mushroom extracts.
Current Marker Systems Fail to Capture Full Bioactive Profile
Eftang contends that marker-based standardization serves identity confirmation but often substitutes for genuine quality assessment. The white paper states that these markers frequently do not represent the complete bioactive profile of Reishi extracts. Commercial quality claims typically focus on compounds that are easier to measure or more familiar in the marketplace, creating a gap between label claims and actual product composition. This disconnect becomes problematic when manufacturers apply generic standards that emphasize industry convention rather than functional chemistry.
Standardized Target Analyte Grouping Framework Introduced
The paper introduces what Nootropics Depot calls the Standardized Target Analyte Grouping (STAG) framework. This approach evaluates Reishi products based on meaningful groups of bioactive compounds instead of isolated marker claims. Reishi contains multiple classes of compounds with different pharmacological relevance, according to the paper. The STAG framework directs quality assessment toward compound groupings that reflect intended biological activity rather than legacy marker systems that may be incomplete when used alone.
Analytical Methodology Shifts Toward Functional Specificity
The white paper calls for clearer target selection and more transparent analytical methodologies. Specifications should tie directly to the active chemistry of the ingredient, not to legacy marker systems, according to Eftang. The paper positions this shift as an opportunity for manufacturers and laboratories to build more auditable and scientifically coherent standards. The framework requires that measured compounds align with the intended biological activity of the finished product, moving beyond basic identity verification.
Publication Continues Company Pattern of Challenging Category Assumptions
Nootropics Depot has published multiple technical papers questioning established ingredient evaluation methods. The company released an electrolyte white paper arguing that legacy frameworks shape modern supplement categories long after their original use case has changed. That paper called for context-driven standards tied to real-world function and formulation intent. The new Reishi paper applies the same principle to mushroom quality, examining whether measured compounds are truly the ones that matter most for product efficacy.
CEO Links Quality Standards to Consumer Purchase Intent
Eftang stated that Reishi has a long history of use, but standardization to specific bioactives is a recent advancement. Modern quality language often reduces that complexity to a few convenient markers, he said. The white paper examines whether those markers provide necessary quality information and how a bioactives-first framework could improve transparency and analytical rigor. Eftang noted that consumers purchase products for an intended effect, and if products contain none of the bioactives that produce that effect, consumers waste their money.
Company Operates with Scientific Advisory Board and Third-Party Laboratory Network
Founded in 2013, Nootropics Depot focuses on ingredient-first product design and analytical transparency. The company evaluates ingredients by examining relevant compounds, extraction methods, standardization targets, effective dosing strategies, and testing requirements. A Scientific Advisory Board of physicians, Ph.D. researchers, and botanists provides input on product development. The company maintains partnerships with third-party laboratories and collaborates with the Future Nutra Foundation. All products include publicly available Certificates of Analysis.
The white paper is available on the Nootropics Depot website. For more information about the company's analytical standards and product development approach, visit https://nootropicsdepot.com/.